Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient.

Jun SY, Jung GM, Yoon SJ, Choi YJ, Koh WS, Moon KS, Kang SH.

Antimicrob Agents Chemother. 2014;58(4):2084-8. doi: 10.1128/AAC.02232-13. Epub 2014 Jan 21.

2.

Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers.

Jun SY, Jang IJ, Yoon S, Jang K, Yu KS, Cho JY, Seong MW, Jung GM, Yoon SJ, Kang SH.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02629-16. doi: 10.1128/AAC.02629-16. Print 2017 Jun.

3.

Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period.

Jun SY, Jung GM, Yoon SJ, Youm SY, Han HY, Lee JH, Kang SH.

Clin Exp Pharmacol Physiol. 2016 Oct;43(10):1013-6. doi: 10.1111/1440-1681.12613.

PMID:
27341401
4.

Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1.

Jun SY, Jung GM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, Kong JC, Seol JG, Kang SH.

Int J Antimicrob Agents. 2013 Feb;41(2):156-61. doi: 10.1016/j.ijantimicag.2012.10.011. Epub 2012 Dec 28.

PMID:
23276502
5.

Bacteriophage endolysins as a novel class of antibacterial agents.

Borysowski J, Weber-Dabrowska B, Górski A.

Exp Biol Med (Maywood). 2006 Apr;231(4):366-77. Review.

PMID:
16565432
6.

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

Jun SY, Jung GM, Son JS, Yoon SJ, Choi YJ, Kang SH.

Antimicrob Agents Chemother. 2011 Apr;55(4):1764-7. doi: 10.1128/AAC.01097-10. Epub 2011 Jan 24.

7.

NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).

National Toxicology Program .

Natl Toxicol Program Tech Rep Ser. 1993 Sep;422:1-340.

9.

Characterization of five novel endolysins from Gram-negative infecting bacteriophages.

Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R.

Appl Microbiol Biotechnol. 2013 May;97(10):4369-75. doi: 10.1007/s00253-012-4294-7. Epub 2012 Jul 26.

PMID:
22832988
10.
12.

Assessment of oral toxicity and safety of 9-cis-UAB30, a potential chemopreventive agent, in rat and dog studies.

Lindeblad M, Kapetanovic IM, Kabirov KK, Dinger N, Mankovskaya I, Morrisey R, Martín-Jiménez T, Lyubimov A.

Drug Chem Toxicol. 2011 Jul;34(3):300-10. doi: 10.3109/01480545.2010.536771.

PMID:
21649485
15.
16.

Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.

Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H.

Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. Review.

PMID:
8486501
17.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
18.

Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.

Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, Eiseman JL, Holleran JL, Sausville EA, Tomaszewski JE.

Cancer Chemother Pharmacol. 2005 Dec;56(6):637-47. Epub 2005 Jun 29.

PMID:
15986212
19.

Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs.

Werley MS, McDonald P, Lilly P, Kirkpatrick D, Wallery J, Byron P, Venitz J.

Toxicology. 2011 Sep 5;287(1-3):76-90. doi: 10.1016/j.tox.2011.05.015. Epub 2011 Jun 12.

PMID:
21683116
20.

Final report on the safety assessment of Trichloroethane.

[No authors listed]

Int J Toxicol. 2008;27 Suppl 4:107-38. doi: 10.1080/10915810802550835.

PMID:
19101834

Supplemental Content

Support Center